These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 17224657

  • 1. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
    Ansari M, Krajinovic M.
    Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
    [Abstract] [Full Text] [Related]

  • 2. Pharmacogenomics of childhood acute lymphoblastic leukemia.
    Brenner TL, Pui CH, Evan WE.
    Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
    [Abstract] [Full Text] [Related]

  • 3. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
    Davidsen ML, Dalhoff K, Schmiegelow K.
    J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
    [Abstract] [Full Text] [Related]

  • 4. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
    Kager L.
    J BUON; 2009 Sep; 14 Suppl 1():S181-6. PubMed ID: 19785064
    [Abstract] [Full Text] [Related]

  • 5. [Pharmacogenomics of acute lymphoblastic leukemia].
    Ansari M, St-Onge G, Krajinovic M.
    Med Sci (Paris); 2007 Nov; 23(11):961-7. PubMed ID: 18021708
    [Abstract] [Full Text] [Related]

  • 6. Pharmacogenomics of acute leukemia.
    Ansari M, Krajinovic M.
    Pharmacogenomics; 2007 Jul; 8(7):817-34. PubMed ID: 18240908
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene.
    Pietrzyk JJ, Bik-Multanowski M, Balwierz W, Skoczen S, Wojcik D, Chybicka A, Sikorska-Fic B, Matysiak M, Szczepanski T, Sonta-Jakimczyk D, Ploszynska A, Balcerska A, Mycko K, Bodalski J, Krawczuk-Rybak M, Kowalczyk J, Koltan A, Sobol G, Derwich K, Kwinta P.
    Pediatr Blood Cancer; 2009 Mar; 52(3):364-8. PubMed ID: 18989887
    [Abstract] [Full Text] [Related]

  • 15. Pathobiology and clinical significance of molecular genetic findings in childhood tumors.
    Rubnitz JE, Downing JR, Crist WM.
    Adv Pediatr; 1998 Mar; 45():315-36. PubMed ID: 9742307
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y.
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P, Landman-Parker J, Cayuela JM, Asnafi V, Labopin M, Gandemer V, Perel Y, Michel G, Leblanc T, Schmitt C, Fasola S, Hagemejier A, Sigaux F, Auclerc MF, Douay L, Leverger G, Baruchel A.
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [Abstract] [Full Text] [Related]

  • 20. Where can biology of childhood ALL be attacked by new compounds?
    Bourquin JP, Izraeli S.
    Cancer Treat Rev; 2010 Jun; 36(4):298-306. PubMed ID: 20223597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.